Literature DB >> 15762184

Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients.

Frederik A Verburg1, Bart de Keizer, Cornelis J M Lips, Pierre M J Zelissen, John M H de Klerk.   

Abstract

OBJECTIVES: Currently, little is known about the prognostic significance of achieving successful ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study aimed to assess the following: (i) whether successful or unsuccessful ablation at post-ablation follow-up has prognostic consequences; (ii) possible factors predicting success of ablation in a patient.
METHODS: In order to do this, we retrospectively studied 180 patients with a median follow-up of 55 months. Ablation was considered to be successful if 1 year after the initial dosage of I-131 patients fulfilled all of the following criteria: not dead from thyroid cancer, no additional therapy needed for any kind for thyroid cancer within the first year, undetectable thyroglobulin (Tg) levels under TSH stimulation, and negative I-131 scintigraphy. Tg levels at the time of ablation (P < 0.001), lymph node metastasis (P = 0.04) and distant metastasis (P < 0.001) have a significant influence on the success of ablation. P values were calculated by Mann-Whitney U test and Chi-square test, respectively.
RESULTS: Patients with successful ablation had a better prognosis than those with unsuccessful ablation: disease-free survival was 87% versus 49% after 10 years; additionally, thyroid-cancer related survival was 93% versus 78%.
CONCLUSION: We conclude that the extent of the remaining normal or neoplastic thyroid tissue influences the outcome of ablation, and that successful ablation leads to a better prognosis. It seems that it is very important to achieve complete ablation as soon as possible in order to ensure the best possible prognosis for a patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762184     DOI: 10.1530/eje.1.01819

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  27 in total

Review 1.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

2.  Decreased radioiodine uptake of FRTL-5 cells after (131)I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway.

Authors:  Birgit Meller; Erzsébet Gaspar; Wibke Deisting; Barbara Czarnocka; Manfred Baehre; Björn E Wenzel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-29       Impact factor: 9.236

Review 3.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine.

Authors:  Frederik A Verburg; Alexander Heinzel; Heribert Hänscheid; Felix M Mottaghy; Markus Luster; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-06       Impact factor: 9.236

5.  Continuous re-evaluation in differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Christoph Reiners
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

Review 6.  Differentiated thyroid cancer-personalized therapies to prevent overtreatment.

Authors:  Markus Luster; Theresia Weber; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2014-07-01       Impact factor: 43.330

7.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

8.  Persistent disease in patients with papillary thyroid carcinoma and lymph node metastases after surgery and iodine-131 ablation.

Authors:  Frederik A Verburg; Bart de Keizer; Marnix G E H Lam; J M H de Klerk; Cornelis J M Lips; Inne H M Borel-Rinkes; Johannes W van Isselt
Journal:  World J Surg       Date:  2007-12       Impact factor: 3.352

9.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

10.  The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.

Authors:  Elena-Daphne Thies; Karina Tanase; Uwe Maeder; Markus Luster; Andreas K Buck; Heribert Hänscheid; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.